CP – 152 EFFECTIVENESS AND SAFETY OF BRENTUXIMAB IN HODGKIN'S AND NON-HODGKIN'S LYMPHOMA

Sáez Belló M.[1], Porta Oltra B.[1], Climente Martí M.[1]

[1]Pharmacy Service. University Hospital Dr. Peset. Gaspar Aguilar 90, Valencia (Spain)

PURPOSE

Evaluation of effectiveness and safety of brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin's lymphoma (HL) and systemic anaplastic large-cell lymphoma (ALCL).

MATERIAL AND METHODS

✓ *Type of study*: retrospective observational cohort study.

✓ *Inclusion criteria*: patients with relapsed or refractory HL and ALCL, treated with SGN-35 in monotherapy from 05/2012 to 09/2014.

✓ *Variables:*

Patients	• Age. • Sex. • Type of lymphoma. • Stage. • International Prognostic Index (IPI score).
Previous therapy	• Prior chemotherapy schedule. • Autologous stem-cell transplantation (auto-SCT).
Actual therapy	• Line of treatment. • Number of cycles. • Dose reductions. • Clinical response according to the Revised Response Criteria for Malignant Lymphoma: complete remission (CR), partial remission (PR), stable disease (SD) and progressed disease (PD). • Incidence and severity of side effects (CTCAE v4.03 criteria).

RESULTS

5 patients	• 47 (30;52) years old. • 3 women, 2 men. • 4 HL, stages II-A, II-B, III-A, IV-B, and 1 ALCL stage IV-A. • IPI score 3 in 2 patients (2 patients not specified).
Previous therapy	• 3 (2;4) chemotherapy schedule before SGN-35. • 3 auto-SCT.
SNG-35	• 4th line (3;6) of treatment. • 4 (3;14) cycles. • 17% reduction of dose in 1 patient (previous hepatic impairment). • **2 CR, 1 PR** and **1 PD**. At the end of the following, 3 patients carried on with the treatment (1 without response evaluation) and 2 patients were exitus (1 CR and 1 PD) with a **time to progression of 2,5(2;3) months**. • Facial rash and a post-infusion reaction grades I-II in 1 patient.

Figure 1. Schedules of treatment.



DISCUSSION AND CONCLUSIONS

The phase II study, that justified the authorization of the drug, showed similar objective response (76/102, 75%) with manageable toxicities.

In our population 3 of 4 patients treated with SGN-35 reached an objective response during 2.5 months, with favourable safety profile.

saez_marbel@gva.es